References
- Serafini B, Rosicarelli B, Franciotta D et al. Dysregulated Epstein–Barr virus infection in the multiple sclerosis brain. J. Exp. Med.204, 2899–2912 (2007).
- Ascherio A, Munger KL. Environmental risk factors for multiple sclerosis. Part I: the role of infection. Ann. Neurol.61, 288–299 (2007).
- Gale CR, Martyn CN. Migrant studies in multiple sclerosis. Prog. Neurobiol.47, 425–448 (1995).
- Kurtzke JF, Hyllested K. Multiple sclerosis in the Faroe Islands. I. Clinical and epidemiological features. Ann. Neurol.5, 6–21 (1979).
- Bach JF. The effect of infections on susceptibility to autoimmune and allergic diseases. N. Engl. J. Med.347, 911–920 (2002).
- Ascherio A, Munch M. Epstein–Barr virus and multiple sclerosis. Epidemiology11, 220–224 (2000).
- Alotaibi S, Kennedy J, Tellier R, Stephens D, Banwell B. Epstein–Barr virus in pediatric multiple sclerosis. JAMA291, 1875–1879 (2004).
- Pohl D, Krone B, Rostasy K et al. High seroprevalence of Epstein–Barr virus in children with multiple sclerosis. Neurology67, 2063–2065 (2006).
- Thacker EL, Mirzaei F, Ascherio A. Infectious mononucleosis and risk for multiple sclerosis: a meta-analysis. Ann. Neurol.59, 499–503 (2006).
- Nielsen TR, Rostgaard K, Nielsen NM et al. Multiple sclerosis after infectious mononucleosis. Arch. Neurol.64, 72–75 (2007).
- Ascherio A, Munger KL, Lennette ET et al. Epstein–Barr virus antibodies and risk of multiple sclerosis: a prospective study. JAMA286, 3083–3088 (2001).
- Levin LI, Munger KL, Rubertone MV et al. Temporal relationship between elevation of Epstein–Barr virus antibody titers and initial onset of neurological symptoms in multiple sclerosis. JAMA293, 2496–2500 (2005).
- DeLorenze GN, Munger KL, Lennette E et al. Epstein–Barr virus and multiple sclerosis: evidence of association from a prospective study with long-term follow-up. Arch. Neurol.63, 839–844 (2006).
- Sundstrom P, Juto P, Wadell G et al. An altered immune response to Epstein–Barr virus in multiple sclerosis: a prospective study. Neurology62, 2277–2282 (2004).
- Kusunoki Y, Huang H, Fukuda Y et al. A positive correlation between the precursor frequency of cytotoxic lymphocytes to autologous Epstein–Barr virus-transformed B cells and antibody titer level against Epstein–Barr virus-associated nuclear antigen in healthy seropositive individuals. Microbiol. Immunol.37, 461–469 (1993).
- Sitki-Green D, Covington M, Raab-Traub N. Compartmentalization and transmission of multiple Epstein–Barr virus strains in asymptomatic carriers. J. Virol.77, 1840–1847 (2003).
- Warner HB, Carp RI. Multiple sclerosis and Epstein–Barr virus (letter). Lancet2, 1290 (1981).
- Hammond SR, English DR, McLeod JG. The age-range of risk of developing multiple sclerosis: evidence from a migrant population in Australia. Brain123, 968–974 (2000).
- James JA, Neas BR, Moser KL et al. Systemic lupus erythematosus in adults is associated with previous Epstein–Barr virus exposure. Arthritis Rheum.44, 1122–1126. (2001).
- Moutschen M, Leonard P, Sokal EM et al. Phase I/II studies to evaluate safety and immunogenicity of a recombinant gp350 Epstein–Barr virus vaccine in healthy adults. Vaccine25, 4697–4705 (2007).
- Lycke J, Svennerholm B, Hjelmquist E et al. Acyclovir treatment of relapsing-remitting multiple sclerosis. A randomized, placebo-controlled, double-blind study. J. Neurol.243, 214–224 (1996).
- Bech E, Lycke J, Gadeberg P et al. A randomized, double-blind, placebo-controlled MRI study of anti-herpes virus therapy in MS. Neurology58, 31–36 (2002).
- Friedman JE, Zabriskie JB, Plank C et al. A randomized clinical trial of valacyclovir in multiple sclerosis. Mult. Scler.11, 286–295 (2005).
- Hemmer B and Hartung HP. Toward the development of rational therapies in multiple sclerosis: what is on the horizon? Ann. Neurol.62, 314–326 (2007).